NIP
LVTX

Nicholas Investment Partners’s LAVA Therapeutics LVTX Stock Holding History

Nicholas Investment Partners’s Portfolio LVTX Stock Details LVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-450,556
Closed -$1.29M – 190
2022
Q2 		$1.29M Sell
450,556
-73,364
-14% -$254K 0.12% 141
2022
Q1 		$2.31M Hold
523,920
– – 0.16% 138
2021
Q4 		$2.88M Sell
523,920
-5,033
-1% -$33K 0.18% 146
2021
Q3 		$3.13M Sell
528,953
-252,914
-32% -$1.82M 0.23% 133
2021
Q2 		$8.51M Sell
781,867
-32,973
-4% -$409K 0.53% 69
2021
Q1 		$12.4M Buy
+814,840
New +$11.2M 0.86% 46

Other funds holding LVTX

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nicholas Investment Partners's LVTX Position: Q3 2022 in Review

Nicholas Investment Partners sold out of LAVA Therapeutics (LVTX) in Q3 2022, closing a stake of 450,556 shares — an estimated $1.29M sold.

Nicholas Investment Partners first reported a position in LVTX in Q1 2021 and held it in 6 quarters. The position peaked at $12.4M in Q1 2021. 13 funds tracked by Wall St. Rank hold LVTX as of Q3 2022.

  • Nicholas Investment Partners reported no remaining LAVA Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Nicholas Investment Partners sold 450,556 LAVA Therapeutics shares in Q3 2022, an estimated $1.29M.
  • Nicholas Investment Partners first reported a position in LAVA Therapeutics in Q1 2021 and held it in 6 quarters.
  • Nicholas Investment Partners's LAVA Therapeutics position peaked at $12.4M in Q1 2021.
  • 13 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q3 2022.

Based on Nicholas Investment Partners's 13F filing for Q3 2022, filed 14 Nov 2022.